MARKET NEWS

Immunic, Inc. Reports Positive Top-line Data From Phase 2 EMPhASIS Trial
FDA Approves Two Emergency INDs for COVID-19 Outpatient Therapy
Corbus Pharmaceuticals Completes Enrollment in Phase 3 Study
Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial
Catalent Gene Therapy Facility Receives FDA Approval as an Additional Manufacturing Site for AveXis' Gene Therapy
BioAegis Therapeutics Initiates Phase 2 Clinical Trial of its Inflammation Regulator for COVID-19 Treatment

  FEATURED EDITORIAL

  COMPANY PROFILE

For nearly 30 years, DDL has provided extraordinary service and specialized testing expertise to the medical device and pharmaceutical industries. Our reliable quality, responsive attention, and on-schedule completion for packaging, medical device, and combination products testing secures confidence in performance and safety while achieving regulatory compliance. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Biogen & Denali Sign Co-Development/Co-Commercialization Agreement

Biogen & Denali Sign Co-Development/Co-Commercialization Agreement

Biogen Inc. and Denali Therapeutics Inc. recently announced they have signed a binding agreement to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for….

RedHill Biopharma’s Phase 2/3 COVID-19 Study Approved in Mexico

RedHill Biopharma’s Phase 2/3 COVID-19 Study Approved in Mexico

RedHill Biopharma Ltd. recently announced approval from the Mexican Federal Committee for the Protection against Sanitary Risks (COFEPRIS) for the company’s Clinical Trial Authorization (CTA) application for….

Immatics Extends Cell Therapy Manufacturing Collaboration With UTHealth

Immatics Extends Cell Therapy Manufacturing Collaboration With UTHealth

Immatics N.V. recently announced the extension of its cell therapy manufacturing collaboration with The University of Texas Health Science Center at Houston (UTHealth)….

Catalent Adds Potent Manufacturing Capabilities at its Buenos Aires Site

Catalent Adds Potent Manufacturing Capabilities at its Buenos Aires Site

Catalent recently announced that it will expand its Argentinian site in Loma Hermosa, Buenos Aires. The expansion, which will add over….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 19 – ODT/Fast Dissolve
August 26 – Transdermal/Topical Delivery